Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023
- Tuesday, June 6, 2023, 7:10
- Business
- Add a comment
VANCOUVER, BC, June 6, 2023 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results in advanced gastric and biliary tract cancer at the 2023 American Society of Clinical Oncology…
About the Author
adminasapcorp has written 39386 stories on this site.